natgillin/translations-raw huggingface dataset:
In addition, rosiglitazone preserved ß-cell function as shown by increased pancreatic islet mass and insulin content and prevented the development of overt hyperglycaemia in animal models of type 2 diabetes. 
Poleg tega je rosiglitazon pri živalskih modelih s sladkorno boleznijo tipa 2 ohranjal tudi delovanje β-celic, kar dokazuje zvečanje mase pankreasnih otočkov in vsebnosti insulina, ter preprečeval nastanek očitne hiperglikemije.
However, in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8). 
V celoti pa razpoložljivi podatki ne omogočajo dokončnega sklepa o tveganju za srčne ishemije(glejte poglavje 4.8).
• rapid increase in your weight 
• hitro povečanje telesne mase.
The major metabolite (a para-hydroxy-sulphate) with high affinity to the soluble human PPARγ, exhibited relatively high potency in a glucose tolerance assay in obese mice. 
Glavni metabolit (parahidroksisulfat) z močno afiniteto do topnega humanega PPARγ je v raziskavi, ki je preučevala toleranco za glukozo pri debelih miših, izkazal sorazmerno visoko učinkovitost.
Clinical trial data (addition of insulin to established AVANDAMET therapy) In a single study (n=322) where insulin was added to patients established on AVANDAMET, no new adverse events were observed in excess of those already defined for either AVANDAMET or rosiglitazone combination therapies. 
V eni študiji (n=322), v kateri je bilo bolnikom, ki so se zdravili z zdravilom AVANDAMET, uvedeno še zdravljenje z insulinom, niso opazili novih neželenih dogodkov, ki bi bili pogostejši od že ugotovljenih, bodisi za zdravilo AVANDAMET bodisi za kombinirano zdravljenje z rosiglitazonom.
The active substances are rosiglitazone and metformin. 
Zdravilni učinkovini sta rosiglitazon in metformin.
Skin and subcutaneous tissue disorders (see Immune system disorders) Angioedema 
Bolezni kože in podkožja (glejte Bolezni imunskega sistema) angioedem
Increased monitoring of the patient and a reduction in the dose of the concomitant agent may be necessary. 
Bolnika bo morda treba skrbno nadzirati, odmerek sočasno vzete zdravilne učinkovine pa zmanjšati.
2 An increased incidence of heart failure has been observed when rosiglitazone was added to treatment regimens with a sulphonylurea (either as dual or triple therapy), and appeared higher with 8 mg rosiglitazone compared to 4 mg rosiglitazone (total daily dose). 
2 Če so rosiglitazon dodali k režimu zdravljenja s sulfonilsečnino (bodisi pri zdravljenju z dvema zdraviloma bodisi pri zdravljenju s tremi zdravili), so opazili večjo pojavnost srčnega popuščanja, ki je bila pri 8 mg odmerku rosiglitazona večja kot pri 4 mg odmerku (skupni dnevni odmerek).
Elderly: In the pooled population pharmacokinetic analysis, age was not found to influence the pharmacokinetics of rosiglitazone to any significant extent. 
Starostniki: Pri preučevanju farmakokinetike znotraj posameznih skupin bolnikov niso opazili, da bi starost kakor koli pomembneje vplivala na farmakokinetiko rosiglitazona.
Adverse reactions are presented below for each of the component parts of AVANDAMET. 
V nadaljevanju so navedeni neželeni učinki vsake od sestavin zdravila AVANDAMET.
An in vivo interaction study with warfarin indicated that rosiglitazone does not interact with CYP2C9 substrates in vivo. 
Študija in vivo je o interakcijah z varfarinom pokazala, da rosiglitazon in vivo s substrati CYP2C2 medsebojno ne učinkuje.
AVANDAMET combines two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: rosiglitazone maleate, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class. 
Zdravilo AVANDAMET je kombinacija dveh antihiperglikemičnih učinkovin s komplementarnim mehanizmom delovanja, namenjeno pa je izboljšanju urejenosti glikemije pri bolnikih s sladkorno boleznijo tipa 2: rosiglitazonijevega maleata iz skupine tiazolidindionov in metforminijevega klorida iz skupine bigvanidov.
Rosiglitazone was associated with increases in weight. 
Rosiglitazon so povezovali s povečevanjem telesne mase.
Premenopausal women have received rosiglitazone during clinical studies. 
V kliničnih študijah so rosiglitazon dajali ženskam pred menopavzo.
There was a significant increase in heart failure (fatal and nonfatal) (HR 2.10, CI 1.35-3.27) and bone fractures (Risk Ratio 1.57, CI 1.26-1.97) in rosiglitazonecontaining treatments compared to active control (see sections 4.4 and 4.8). 
Med zdravljenji, ki so vključevala rosiglitazon, so v primerjavi s primerjalno učinkovino ugotovili značilno več srčnega popuščanja (s smrtnim izidom ali brez njega) (razmerje ogroženosti 2,10, IZ 1,35-3,27) in zlomov kosti (razmerje tveganj 1,57, IZ 1,26-1,97) (glejte poglavji 4.4 in 4.8).
The relevance of this finding is unknown. 
Klinični pomen teh ugotovitev ni poznan.
An adjusted mean reduction in HbA1c of 0.24% was seen for patients taking rosiglitazone added to sulphonylurea, versus a reduction in HbA1c of 0.10% for patients taking metformin added to sulphonylurea, (p=0.0083 for treatment difference). 
Pri bolnikih, ki so jemali rosiglitazon dodan sulfonilsečnini, so ugotovili korigirano povprečno znižanje HbA1c za 0,24 %, pri bolnikih, ki so jemali metformin dodan sulfonilsečnini, pa znižanje za 0,10 % (p = 0,0083 za razliko med zdravljenji).
Not all pack sizes or tablet strengths may be available in your country. 
Na trgu ni vseh navedenih pakiranj ali jakosti tablet.
Rosiglitazone treatment significantly reduced the risk of reaching monotherapy failure (FPG>10.0 mmol/L) by 63% relative to glibenclamide (HR 0.37, CI 0.30-0.45) and by 32% relative to metformin (HR 0.68, CI 0.55-0.85) during the course of the study (up to 72 months of treatment). 
Med študijo (do 72 mesecev zdravljenja) je zdravljenje z rosiglitazonom statistično značilno zmanjšalo tveganje odpovedi monoterapije (glukoza v plazmi na tešče > 10,0 mmol/l) za 63 % v primerjavi z glibenklamidom (razmerje ogroženosti 0,37, interval zaupanja 0,30-0,45) in za 32 % v primerjavi z metforminom (razmerje ogroženosti 0,68, interval zaupanja 0,55-0,85).
If necessary, the dosage of the antihyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation. 
Če je potrebno, odmerek antidiabetikov prilagodimo bodisi zdravljenju z drugimi zdravili bodisi ukinitvi zdravljenja s takšnimi zdravili.
Non-clinical data for metformin reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction. 
Predklinični podatki o metforminu, ki se naslanjajo na običajne farmakološke raziskave o varnosti, toksičnosti pri večkratnih odmerkih, kancerogenem delovanju in vplivih na sposobnost razmnoževanja, ne kažejo na posebno tveganje za ljudi.
After an oral dose of metformin, tmax is reached in 2.5 h. Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects. 
Pri zdravih posameznikih je absolutna biološka uporabnost 500 mg tablete metformina približno 50 do 60 %.
Renal insufficiency: There are no clinically significant differences in the pharmacokinetics of rosiglitazone in patients with renal impairment or end stage renal disease on chronic dialysis. 
Insuficienca ledvic: Pri bolnikih z oslabljenim delovanjem ledvic ali v zadnjem stadiju ledvične bolezni in s kronično dializo niso zasledili klinično pomembnih razlik v farmakokinetiki rosiglitazona.
In the final analysis at 5 years, an adjusted mean reduction from baseline in HbA1c of 0.14% for patients on rosiglitazone added to metformin versus an increase of 0.17% for patients taking sulphonylurea added to metformin was seen during treatment with randomised dual-combination therapy (p<0.0001 for treatment difference). 
V končni analizi po 5 letih so med uporabo randomiziranega dvotirnega kombiniranega zdravljenja pri bolnikih z rosiglitazonom dodanim metforminu ugotovili korigirano povprečno znižanje HbA1c v primerjavi z izhodiščem za 0,14 %, pri bolnikih s sulfonilsečnino dodano metforminu pa zvišanje za 0,17 % (p < 0,0001 za razliko med zdravljenji).
Following rosiglitazone treatment, there were no new safety concerns noted in children compared to adult patients with type 2 diabetes mellitus. 
V primerjavi z odraslimi bolniki s sladkorno boleznijo tipa 2 pri otrocih pri zdravljenju z rosiglitazonom niso zaznali dodatnih težav z varnostjo.
AVANDAMET should be used with caution during concomitant administration of CYP2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin), due to the effect on rosiglitazone pharmacokinetics (see section 4.5). 
V primeru sočasnega dajanja zaviralcev CYP2C8 (npr. gemfibrozil) ali induktorjev CYP2C8 (npr. rifampicin) in zdravila AVANDAMET je slednjega, zaradi učinka na farmakokinetiko rosiglitazona, potrebno uporabljati previdno (glejte poglavje 4.5).
Marketing Authorisation Holder: SmithKline Beecham Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. 
Imetnik dovoljenja za promet z zdravilom: SmithKline Beecham Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija.
These may affect more than 1 in 10 people: 
Pojavijo se lahko pri več kot 1 od 10 bolnikov:
Rosiglitazone treatment is associated with a dose-related reduction of haemoglobin levels. 
Zdravljenje z rosiglitazonom je povezano z od odmerka odvisnim zmanjšanjem koncentracije hemoglobina.
These may affect up to 1 in 1,000 people: 
Pojavijo se lahko pri do 1 od 1.000 bolnikov:
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h. When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma. 
V primeru oslabljene funkcijske sposobnosti ledvic se ledvični očistek zmanjša v sorazmerju s kreatininskim in tako se razpolovna doba izločanja podaljša, kar vodi v zvečanje vrednosti metformina v plazmi.
The doctor will check your kidney function before restarting treatment. 
Pred nadaljevanjem zdravljenja bo zdravnik preveril delovanje ledvic.
Avandamet contains lactose 
Zdravilo Avandamet vsebuje laktozo
Blood and the lymphatic system disorders Anaemia granulocytopaenia 
Bolezni krvi in limfatičnega sistema anemija
After oral administration, metformin absorption is saturable and incomplete. 
Po peroralnem odmerku je absorpcija metformina nepopolna in poteka do zasičenja.
Î Tell your doctor as soon as possible if you get these symptoms. 
Î Čimprej obvestite svojega zdravnika, če se pojavijo ti simptomi.
The usual starting dose of AVANDAMET is 4 mg/day rosiglitazone plus 2000 mg/day metformin hydrochloride. 
Običajni začetni odmerek zdravila AVANDAMET je 4 mg/dan rosiglitazona in 2000 mg/dan metforminijevega klorida.
Therapy with AVANDAMET should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 times the upper limit of normal) or with any other evidence of liver disease. 
Pri bolnikih z zvišanimi osnovnimi vrednostmi jetrnih encimov (ALT > 2,5-krat od zgornje meje normalne vrednosti) ali s katerimi koli drugimi znaki jetrnega obolenja se zdravljenje z zdravilom AVANDAMET ne sme uvesti.
An active controlled clinical trial (rosiglitazone up to 8 mg daily or metformin up to 2,000 mg daily) of 24 weeks duration was performed in 197 children (10-17 years of age) with type 2 diabetes. 
Pri 197 otrocih (starih od 10 do 17 let) s sladkorno boleznijo tipa 2 je bilo izvedeno 24-tedensko z učinkovino nadzorovano klinično preskušanje (rosiglitazon do 8 mg na dan ali metformin do 2.000 mg na dan).
Gastrointestinal disorders gastrointestinal symptoms6 
Bolezni prebavil prebavni simptomi6
The frequency of adverse reactions identified from clinical trial data with rosiglitazone Adverse reaction 
Pogostnost neželenih učinkov na osnovi podatkov iz kliničnih preskušanj rosiglitazona
SmithKline Beecham Ltd 980 Great West Road Brentford, Middlesex TW8 9GS United Kingdom 
SmithKline Beecham Ltd 980 Great West Road Brentford, Middlesex TW8 9GS Velika Britanija
No statistically significant difference was observed between the absorption characteristics of rosiglitazone and metformin from the AVANDAMET tablet and those obtained from rosiglitazone maleate and metformin hydrochloride tablets, respectively. 
AVANDAMET Absorpcija Značilnost absorpcije rosiglitazona in metformina v zdravilu AVANDAMET se statistično značilno ne razlikuje od posamičnih absorpcij rosiglitazonijevega maleata in metforminijevega klorida.
• lower blood sugar than normal (hypoglycaemia) 
• prekomerno znižanje vrednosti krvnega sladkorja (hipoglikemija).
• rapid and excessive weight gain caused by fluid retention 
• hitro in močno povečanje telesne mase zaradi kopičenja tekočine v telesu.
Immune system disorders (see Skin and subcutaneous tissue disorders) anaphylactic reaction 
Bolezni imunskega sistema (glejte Bolezni kože in podkožja) anafilaktična reakcija
- hypersensitivity to rosiglitazone, to metformin hydrochloride or to any of the excipients - cardiac failure or history of cardiac failure (New York Heart Association (NYHA) stages I to IV) - an Acute Coronary Syndrome (unstable angina, NSTEMI and STEMI) (see section 4.4) - acute or chronic disease which may cause tissue hypoxia such as: - cardiac or respiratory failure - recent myocardial infarction - shock - hepatic impairment - acute alcohol intoxication, alcoholism (see section 4.4) - diabetic ketoacidosis or diabetic pre-coma - renal failure or renal dysfunction e.g. serum creatinine levels > 135 µmol/l in males and > 110 µmol/l in females and/or creatinine clearance < 70 ml/min (see section 4.4) - acute conditions with the potential to alter renal function such as: - dehydration - severe infection - shock - intravascular administration of iodinated contrast agents (see section 4.4) - lactation. 
- oslabljenem delovanju jeter; - akutni zastrupitvi z alkoholom, alkoholizmu (glejte poglavje 4.4); - diabetični ketoacidozi ali diabetični komi; - ledvični odpovedi ali ledvični disfunkciji, npr. koncentracija kreatinina v serumu > 135 μmol/l pri moških ter serumska koncentracija kreatinina > 110 μmol/l pri ženskah in/ali očistek kreatinina < 70 ml/min (glejte poglavje 4.4); - akutnih stanjih, ki lahko spremenijo delovanje ledvic: - dehidracija - hude okužbe - šok - intravaskularna uporaba jodiranih kontrastnih sredstev (glejte poglavje 4.4);
These strengths are supplied in blister packs containing 14, 28, 56, 2x56, 3x56 or 180 film-coated tablets. 
Pakiranje vsebuje 14, 28, 56, 2x56, 3x56 ali 180 filmsko obloženih tablet.
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed: - a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034 - a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017 - a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021) - a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years (p=0.01). 
Analize teh rezultatov pri bolnikih s čezmerno telesno maso, ki so bili po neuspešnem zdravljenju samo z dieto zdravljeni z metforminom, kažejo: - značilno zmanjšanje absolutnega tveganja za katero koli s sladkorno boleznijo povezano komplikacijo v skupini bolnikov, ki so se zdravili z metforminom (29,8 primerov/1.000 bolnikov letno), v primerjavi s skupino bolnikov, ki je imela predpisano zgolj dieto (43,3 primerov/1.000 bolnikov letno), p = 0,0023 ter v primerjavi s skupino, ki se je kombinirano zdravila s sulfonilsečnino, in skupino, ki je imela monoterapijo z insulinom (40,1 primerov/1.000 bolnikov letno), p = 0,0034; - značilno zmanjšanje absolutnega tveganja za umrljivost, povezano s sladkorno boleznijo: metformin - 7,5 primerov/1.000 bolnikov letno, samo dieta - 12,7 primerov/1.000 bolnikov
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, 
Incidenco laktacidoze je možno in tudi potrebno zmanjševati z oceno drugih povezanih dejavnikov tveganja, kot so slabo nadzorovana sladkorna bolezen, ketoza, dolgotrajno stradanje, čezmerno uživanje alkohola, jetrna insuficienca in katera koli stanja, povezana s hipoksijo.
Cardiac disorders cardiac failure2 
Srčne bolezni srčno popuščanje2
Dose titration with rosiglitazone (added to the optimal dose of metformin) may be considered before the patient is switched to AVANDAMET. 
Preden se bolnika preusmeri na zdravljenje z zdravilom AVANDAMET, se lahko najprej pretehta možnost uravnavanja odmerka rosiglitazona (dodajanje k optimalnemu odmerku metformina).
The frequency of adverse reactions identified from post-marketing data with rosiglitazone 
Pogostnost neželenih učinkov na osnovi podatkov po pridobitvi dovoljenja za promet rosiglitazona
Don't take Avandamet. 
Ne jemljite zdravila Avandamet.
Rosiglitazone did not stimulate pancreatic insulin secretion or induce hypoglycaemia in rats and mice. 
Rosiglitazon pri miših in podganah ni spodbujal izločanja insulina iz trebušne slinavke ali sprožil hipoglikemije.
• swelling (oedema) due to water retention 
• oteklina (edem) zaradi zastajanja vode v telesu.
Heart failure was also reported more frequently in patients with a history of heart failure; oedema and heart failure was also reported more frequently in elderly patients and in patients with mild or moderate renal failure. 
O edemih in srčnem popuščanju so pogosteje poročali tudi pri starostnikih in pri bolnikih z blago do zmerno odpovedjo ledvic.
Hepatobiliary disorders hepatic dysfunction, primarily evidenced by elevated hepatic enzymes5 
Bolezni jeter, žolčnika in žolčevodov disfunkcija jeter, ki se prvenstveno kaže s povišanjem vrednosti jetrnih encimov5
An increase in the rosiglitazone component to 8 mg/day should be undertaken cautiously following appropriate clinical evaluation to assess the patient's risk of developing adverse reactions relating to fluid retention (see sections 4.4 and 4.8). 
Pred tem je treba opraviti ustrezen klinični pregled in oceniti bolnikovo ogroženost za pojav neželenih učinkov, povezanih z zastajanjem tekočine (glejte poglavji 4.4 in 4.8).
Overall, 43%, 47% and 42% of subjects in the rosiglitazone, glibenclamide and metformin groups respectively withdrew due to reasons other than monotherapy failure. 
Zaradi drugih razlogov, ne zaradi neuspeha monoterapije, se je v celoti umaknilo 43 % preiskovancev v skupini z rosiglitazonom, 47 % v skupini z glibenklamidom in 42 % v skupini z metforminom.
MULTIPACKS ONLY (2x56 TABLETS, WRAPPED IN CLEAR PLASTIC) MULTIPACKS ONLY (3x56 TABLETS, PACKED IN BOX) 
SAMO ZA PAKIRANJE PO VEČ ENOT (3 x 56 TABLET, PAKIRANIH V ŠKATLO)
Î Tell your doctor as soon as possible if you get any of these symptoms. 
Î Čimprej obvestite svojega zdravnika, če se pojavi katerikoli od teh simptomov.
The incidence of heart failure on triple oral therapy was 1.4% in the main double blind study, compared to 0.4% for metformin plus sulphonylurea dual therapy. 
V obsežni dvojno slepi študiji pri peroralnem zdravljenju s tremi zdravili je bila incidenca srčnega popuščanja 1,4 %, pri režimu zdravljenja z dvema zdraviloma (metformin in sulfonilsečnina) pa 0,4 %.
Hypromellose (E464) Titanium dioxide (E171) Macrogol 
Filmska obloga: hipromeloza (E464) titanov dioksid (E171) makrogol rdeči železov oksid (E172)
Post-marketing data 
Podatki po pridobitvi dovoljenja za promet
PSURs 
PSUR-i
Î Contact a doctor immediately if you get any of these symptoms. 
Î Nemudoma se posvetujte z zdravnikom, če se pojavi katerikoli od teh simptomov.
ADOPT (A Diabetes Outcome Progression Trial) was a multicentre, double-blind, controlled trial with a treatment duration of 4-6 years (median duration of 4 years), in which rosiglitazone at doses of 4 to 8 mg/day was compared to metformin (500 mg to 2000 mg/day) and glibenclamide (2.5 to 15 mg/day) in 4351 drug naive subjects recently diagnosed (≤3 years) with type 2 diabetes. 
V tem preskušanju so rosiglitazon v odmerkih 4 do 8 mg/dan primerjali z metforminom (500 mg do 2000 mg/dan) in glibenklamidom (2,5 do 15 mg/dan) pri 4351 preiskovancih z nedavno odkrito ( ≤3 leta) sladkorno boleznijo tipa 2, ki pred tem še niso dobivali zdravil.
General disorders and administration site conditions Oedema 
Splošne težave in spremembe na mestu aplikacije edem
Metabolism and nutrition disorders lactic acidosis 
Presnovne in prehranske motnje laktacidoza
Individual CL/F in the paediatric population was in the same range as individual adult data. 
Pri posameznem otroku je bil navidezni očistek v istem razponu kot podatki za posameznega odraslega bolnika.
Î Contact a doctor immediately if you get these symptoms. 
Î Nemudoma se posvetujte z zdravnikom, če opazite te simptome.
Food had no effect on the AUC of rosiglitazone or metformin when AVANDAMET was administered to healthy volunteers. 
Pri zdravih prostovoljcih, ki so dobivali AVANDAMET, hrana ni vplivala na AUC rosiglitazona ali metformina.
• nausea and vomiting 
• siljenje na bruhanje in bruhanje.
Nervous system disorders dizziness* 
Bolezni živčevja omotica* glavobol*
Nervous system disorders metallic taste 
Bolezni živčevja okus po kovini
Metabolism and nutrition disorders hypercholesterolaemia1 Common hypertriglyceridaemia Common Hyperlipaemia weight increase increased appetite 
Presnovne in prehranske motnje hiperholesterolemija1 Pogosti
These may affect up to 1 in 10,000 people: 
Pojavijo se lahko pri do 1 od 10.000 bolnikov:
PHARMACEUTICAL FORM AND CONTENTS 112 tablets. 
Vsaka enota vsebuje 112 tablet.
Rosiglitazone failed to demonstrate non-inferiority to metformin. 
Enakovrednosti rosiglitazona metforminu ni bilo mogoče dokazati.
Î Tell a doctor or pharmacist if you are taking any of these. 
Î Obvestite svojega zdravnika, če jemljete katerokoli od teh zdravil.
Therefore, liver enzymes should be checked prior to the initiation of therapy with AVANDAMET in all patients and periodically thereafter based on clinical judgement. 
Pri bolnikih z zvišanimi vrednostmi jetrnih encimov (ALT > 2,5-krat od zgornje meje normalne vrednosti) so izkušnje z rosiglitazonom omejene, zato je pred pričetkom zdravljenja z zdravilom AVANDAMET pri vseh bolnikih potrebno preveriti jetrne encime in jih nato na osnovi klinične presoje preverjati periodično.
Rosiglitazone can be increased to 8 mg/day after 8 weeks if greater glycaemic control is required. 
Če je potrebno močnejše uravnavanje koncentracije glukoze v krvi, se lahko po 8 tednih odmerek rosiglitazona zveča na 8 mg/dan.
How much to take 
Kakšen odmerek zdravila vzeti
These strengths are supplied in blister packs containing 28, 56, 112, 3x112 or 360 film-coated tablets. 
Pakiranje vsebuje 28, 56, 112, 3x112 ali 360 filmsko obloženih tablet.
In an update to this retrospective analysis that included 10 further studies that met the criteria for inclusion, but were not available at the time of the original analysis, the overall incidence of events typically associated with cardiac ischaemia was not statistically different for rosiglitazone containing regimens, 2.21% versus combined active and placebo comparators, 2.08% [HR 1.098 (95% CI 0.809 - 1.354)]. 
Ta posodobitev je pokazala, da se celotna incidenca dogodkov, tipično povezanih s srčno ishemijo pri bolnikih , ki so prejemali rosiglitazon (2,21 %) ni statistično značilno razlikovala od incidence pri bolnikih, ki so prejemali primerjalno učinkovino ali placebo (2,08 %) [razmerje ogroženosti 1,098 (95 % IZ 0,809-1,354)].
tell your doctor before you take Avandamet. 
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO AVANDAMET